Related Experiment Video
Updated: Jun 26, 2026
08:03
In Vivo Mouse Model of Spinal Implant Infection
Published on: June 23, 2020
Evaluation of [(201)Tl](III) Vancomycin in normal rats
Amir Reza Jalilian1, Mohammad Amin Hosseini, Abbas Majdabadi
1Nuclear Medicine Group, Agriculture, Medicine and Industrial Research School (AMIRS), Nuclear Science and Technology Institute, Karaj, Iran. ajalilian@nrcam.org
Nuclear Medicine Review. Central & Eastern Europe
|January 29, 2009
Summary
Thallium-201 (Tl-201) vancomycin complex shows promising biological properties for radiolabeling. Biodistribution studies in rats indicate potential for diagnostic imaging applications.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical chemistry
- Biomedical imaging
Background:
- Thallium-201 (Tl-201) exhibits potential for radiolabeling, analogous to Indium-111 (In-111) and radiogallium.
- This study evaluates the biological properties of a newly synthesized [(201)Tl](III) vancomycin complex ([(201)Tl](III)VAN).
Purpose of the Study:
- To assess the biological characteristics and potential diagnostic applications of the [(201)Tl](III)VAN complex.
- To compare the biodistribution and imaging capabilities of [(201)Tl](III)VAN with established tracers.
Main Methods:
- Preparation of [(201)Tl](III)VAN under optimized conditions.
- Biodistribution studies in normal rats up to 52 hours post-injection.
- In vitro assessment of Staphylococcus aureus specific binding and SPECT imaging in normal animals.
Main Results:
- High radiochemical yield (>99%) and purity (>98%) were achieved for freshly prepared [(201)Tl](III)VAN.
- Biodistribution patterns of [(201)Tl](III)VAN mirrored those of unlabeled vancomycin.
- Microorganism binding ratios indicated preserved bioactivity of the thallium tracer.
Conclusions:
- The [(201)Tl](III)VAN complex demonstrates favorable biological properties for potential use in nuclear medicine.
- Further research may explore its efficacy in targeted imaging and infection detection.
